Also known as Tekturna
Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.Source: Wikipedia
Estimated Total Cost: $82.75 for an average of 28 days supply
Patients are most commonly prescribed aliskiren to treat high blood pressure, coronary atherosclerosis, chronic kidney disease, and rabies.